Skip to main content
. 2019 Oct 22;9:15017. doi: 10.1038/s41598-019-51459-4

Table 3.

Summary of 25 single nucleotide variants subjected to validation experiments.

Gene Sample Chr Genomic position Reference Variant AA change Total number of consensus reads Number of variant reads VAF (%) Validation with tumor DNA by amplicon sequencing Validation with cfDNA by digital PCR
TERT promoter RK436 5 1295228 G A 395 6 1.52 y
TP53 RK432 17 7577120 C T R273H 884 7 0.79 n N/A
TP53 RK451 17 7577133 T C S269G 1,179 3 0.25 n y
TP53 RK258 17 7578503 C T V143M 1,216 106 8.72 y
TP53 RK436 17 7578535 T G K132T 620 61 9.84 y
CTNNB1 RK451 3 41274886 A G Q379R 1,376 22 1.60 y
ARID1A RK445 1 27106316 C T S1976F 1,035 3 0.29 n y
ARID2 RK439 12 46231342 T G Y394X 816 17 2.08 y
ACVR2A RK441 2 148657079 G T E106X 696 8 1.15 y
NFE2L2 RK444 2 178098809 T C E79G 622 5 0.80 n y
NFE2L2 RK441 2 178098956 A C L30R 751 5 0.67 y
RPS6KA3 RK439 X 20193353 T A S386C 397 10 2.52 y
COL11A1 RK456 1 103405977 G A P1097L 1,264 4 0.32 n N/A
COL11A1 RK451 1 103488365 G T P393Q 1,384 10 0.72 n N/A
CTNNA2 RK445 2 80097000 G A R175H 1,079 4 0.37 y
ROBO2 RK432 3 77571995 G T M292I 685 3 0.44 y
CDH9 RK438 5 26902700 G T P380T 1,453 3 0.21 y
APC RK456 5 112175232 G A R1314K 1,174 5 0.43 n y
EPHA7 RK433 6 93956601 C T E879K 615 4 0.65 n N/A
GLI3 RK456 7 42004860 C A A1271S 1,263 7 0.55 n N/A
PREX2 RK442 8 69104007 C T A1466V 857 27 3.15 y
ATM RK442 11 108121480 T G C430G 677 5 0.74 n y
LRFN5 RK445 14 42356455 G C K209N 996 4 0.40 n y
IGF1R RK451 15 99251289 A G N198S 1,275 8 0.63 n y
PAK7 RK439 20 9561315 A C L156R 788 6 0.76 n y

Note: AA, amino acid; VAF, variant allele frequency; cfDNA, cell-free DNA; y, successfully validated; n, NOT validated; N/A: not assessed due to a lack of sample volume for the experiment.